Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
Launched by SIRION THERAPEUTICS, INC. · Jan 31, 2007
Trial Information
Current as of May 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • males or females, 50 to 89 years of age
- • must have GA from AMD in one or both eyes
- Exclusion Criteria:
- • GA due to any disease other than AMD (eg, drug-induced)
About Sirion Therapeutics, Inc.
Sirion Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for ocular diseases. With a focus on advancing cutting-edge treatments, Sirion harnesses proprietary technology and scientific expertise to address unmet medical needs in the ophthalmic space. The company is committed to improving patient outcomes through rigorous clinical trials and collaborations with healthcare professionals, striving to enhance the quality of life for individuals affected by vision-threatening conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Roger Vogel, MD
Study Director
ReVision Therapeutics Advisor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials